Methods to estimate the optimal treatment regime among all linear regimes via smoothed estimation methods, and construct element-wise confidence intervals for the optimal linear treatment regime vector, as well as the confidence interval for the optimal value via wild bootstrap procedures, if the population follows treatments recommended by the optimal linear regime. See more details in: Wu, Y. and Wang, L. (2021), "Resampling-based Confidence Intervals for Model-free Robust Inference on Optimal Treatment Regimes", Biometrics, 77: 465– 476, <doi:10.1111/biom.13337>.

We provide a comprehensive software to estimate general K-stage DTRs from SMARTs with Q-learning and a variety of outcome-weighted learning methods. Penalizations are allowed for variable selection and model regularization. With the outcome-weighted learning scheme, different loss functions - SVM hinge loss, SVM ramp loss, binomial deviance loss, and L2 loss - are adopted to solve the weighted classification problem at each stage; augmentation in the outcomes is allowed to improve efficiency. The estimated DTR can be easily applied to a new sample for individualized treatment recommendations or DTR evaluation.

Dynamic treatment regime estimation and inference via G-estimation, 
  dynamic weighted ordinary least squares (dWOLS) and Q-learning. Inference via 
  bootstrap and recursive sandwich estimation. Estimation and 
  inference for survival outcomes via Dynamic Weighted Survival Modeling (DWSurv). 
  Extension to continuous treatment variables. Wallace et al. (2017) 
  <DOI:10.18637/jss.v080.i02>; Simoneau et al. (2020) 
  <DOI:10.1080/00949655.2020.1793341>.

Provides methods for estimating multi-stage optimal dynamic treatment regimes for survival outcomes with dependent censoring. Cho, H., Holloway, S. T., and Kosorok, M. R. (2020) <arXiv:2012.03294>.

It is a novel tool used to identify the candidate drugs against a particular disease based on the drug target set enrichment analysis. It assumes the most effective drugs are those with a closer affinity in the protein-protein interaction network to the specified disease. (See Gómez-Carballa et al. (2022) <doi: 10.1016/j.envres.2022.112890> and Feng et al. (2022) <doi: 10.7150/ijms.67815> for disease expression profiles; see Wishart et al. (2018) <doi: 10.1093/nar/gkx1037> and Gaulton et al. (2017) <doi: 10.1093/nar/gkw1074> for drug target information; see Kanehisa et al. (2021) <doi: 10.1093/nar/gkaa970> for the details of KEGG database.)